https://www.selleckchem.com/pr....oducts/glafenine.htm
Targeting the epidermal growth factor receptorpathway remains controversial in pancreatic cancer. Afatinib is an oral irreversible ErbB family blocker approved in non-small-cell lung cancer. This open-label, multicenter, randomised phase II trial evaluated gemcitabine plus afatinib (Gem/afatinib) versus gemcitabine (Gem) alone as first-line treatment for metastatic pancreatic cancer. Patients were randomised in a 21 ratio to either Gem (1000mg/m weekly for three weeks followed by one week of rest, repeated every four weeks) and afatin
Like
Comment
Share
